Journal of Traditional Medical Complementary Therapies

.: REVIEW
Kanserden Korunmada Beslenme Tarzının Önemi: Moleküler Düzeyde Bir Bakış
Importance of Nutritional Habits in Cancer Prevention: A Molecular Perspective
Mustafa ÇELEBİERa, Ayşe ERCANb, Yavuz Bülent KÖSEc
aHacettepe Üniversitesi Eczacılık Fakültesi, Analitik Kimya ABD, Ankara, TÜRKİYE
bHacettepe Üniversitesi Eczacılık Fakültesi, Biyokimya ABD, Ankara, TÜRKİYE
cAnadolu Üniversitesi Eczacılık Fakültesi, Farmasötik Botanik ABD, Eskişehir, TÜRKİYE
J Tradit Complem Med. 2021;4(1):109-22
doi: 10.5336/jtracom.2020-76125
Article Language: TR
Full Text
ÖZET
 Hücrelerin kontrolsüz ve anormal bir şekilde çoğalması ile karakterize olan kanser, gelişen ve gelişmekte olan ülkelerde mortalitesi ve morbiditesi en yüksek hastalıktır. Kanserin farklı evrelerinde tedavi amacıyla kemoterapi, radyoterapi ve cerrahi yöntemler kullanılmaktadır. İlaveten prevantif olarak yani hastalıktan korunma amacıyla alternatif tamamlayıcı yöntemlere ve yaşam şartlarında değişikliklere de başvurulmaktadır. Bu bağlamda beslenme tarzı ve kanser oluşum riski arasındaki olası ilişki göz önünde bulundurulunca, kanserden korunmada beslenme tarzının önemi üzerine odaklanan araştırmalar da hız kazanmıştır. Bu derlemenin öncelikli amacı, dünya üzerinde sıklıkla kullanılan besinlerin aktif bileşenlerini temel alarak, etkiledikleri moleküler yolakları açıklamaktır. Yapılan multidisipliner bilimsel araştırmalar göstermiştir ki bu etkileşimler ancak genomik, proteomik ve metabolomik çalışmaların entegre edilmesi ile sağlıklı bir şekilde açıklanmaktadır. 'Foodomik' olarak adlandırılan yaklaşım ile çoklu omik çalışmalar kullanılarak, moleküllerin insan sağlığı üzerindeki etkisi ileri analitik yöntemlerle aydınlatılmaktadır. Bu derleme kapsamında, dünya nüfusunun büyük bir kısmının beslenme alışkanlıklarını teşkil eden 4 büyük mutfak ve vazgeçilmez unsurları sunulmuştur. Akdeniz mutfağı ve önemli unsurlarından zeytinyağı, domates, sarımsak, biberiye, adaçayı; Hint mutfağı ve önemli unsurlarından zerdeçal, sumak, kimyon, zencefil, safran; Çin mutfağı ve önemli unsurlarından soya fasulyesi, pirinç, brokoli; Meksika mutfağı ve önemli unsuru olan Şili biberi incelenmiştir. İlgili aktif bileşenlerin, kanserden korunmada veya kanseri engellemede etkin olduğu metabolik yolaklar üzerine literatür taraması yapılmıştır. Ayrıca bölgelere göre gözlemlenen kanser türlerinin de genel bir değerlendirmesi gerçekleştirilerek, literatür taraması sonucu elde edilen bulgularla ilişkilendirilmiştir. Bu derlemenin; klinisyenler, diyetisyenler ve eczacılar için yararlı bir özet kaynak olması amaçlanmıştır.

Anahtar Kelimeler: Genomik; proteomik; metabolomik; diyet, besin ve beslenme, beslenme davranışı, antineoplastik ajanlar
ABSTRACT
 Characterized by uncontrolled and abnormal growth, cancer is a disease with high mortality and morbidity rates, seen in developed and underdeveloped countries. Chemotherapy, radiotherapy and surgery are methods used to treat different stages of the disease. Additionally, alternative complementary methods and small changes in lifestyle are used preventially to avoid the disease. In this context, considering the possible relationship between nutrition style and the risk of cancer formation, researches focusing on the importance of nutritional choices for cancer prevention has increased dramatically. The primary purpose of this review is to evaluate the nutrients frequently used worldwide by considering their active metabolites and to explain their impact on the molecular pathways. Multidisciplinary scientific researches has shown that these effects can only be explained by the integrating genomic, proteomic and metabolomic studies. Nowadays, the role of small molecules affecting human health is clarified by multi omic studies using advanced analytical methods, called foodomics. In this review, four large cuisines that constitute the nutritional habits of a great majority of the world population and their indispensable elements are presented. Mediterranean cuisine and its important elements olive oil, tomatoes, garlic, rosemary, sage; Indian cuisine and its important elements turmeric, sumac, cumin, ginger, saffron; Chinese cuisine and its important elements soybeans, rice, broccoli; Mexican cuisine and its important element chili pepper are investigated. The relevant active ingredients that effect metabolic pathways and help cancer prevention were screened. Also, a general assessment of cancer types observed based on regions was performed and was associated with the findings obtained from up-to-date scientific researches. This review study is intended to be a useful summary resource for clinicians, dieticians and pharmacists.

Keywords: Genomics; proteomics; metabolomics; diet, food, and nutrition, feeding behavior, antineoplastic agents
REFERENCES:
  1. Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol. 2012;39(3):323-39. [Crossref]  [PubMed]  [PMC] 
  2. Wenger JB, Chun SY, Dang DT, Luesch H, Dang LH. Combination therapy targeting cancer metabolism. Med Hypotheses. 2011;76(2):169-72. [Crossref]  [PubMed]  [PMC] 
  3. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):1397-421. [Crossref]  [PubMed] 
  4. Parkin DM, Coleman MP. Changes in diet and changes in cancer risk: observational studies. IARC Sci Publ. 1990;(103):93-111. [PubMed] 
  5. Cerrato PL. Low-fat diet, lower risk of colorectal cancer. RN. 1991;54(9):71-3. [PubMed] 
  6. Dwyer JT. Diet and nutritional strategies for cancer risk reduction. Focus on the 21st century. Cancer. 1993;72(3 Suppl):1024-31. [Crossref]  [PubMed] 
  7. Hill MJ. Diet, physical activity and cancer risk. Public Health Nutr. 1999;2(3A):397-401. [Crossref]  [PubMed] 
  8. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer. 2004;4(7):519-27. [Crossref]  [PubMed] 
  9. Espey D, Paisano R, Cobb N. Regional patterns and trends in cancer mortality among American Indians and Alaska Natives, 1990-2001. Cancer. 2005;103(5):1045-53. [Crossref]  [PubMed] 
  10. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49(1):33-64, 1. [Crossref]  [PubMed] 
  11. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. [Crossref]  [PubMed] 
  12. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-43. Erratum in: Lancet Oncol 2001;2(10):596. [Crossref]  [PubMed] 
  13. Baykan A, Zorluoğlu A, Geçim E, Terzi C. Kolon ve Rektum Kanserleri. İstanbul: Türk Kolon ve Rektum Cerrahisi Derneği; 2010.
  14. Boran M, Göl H. [Epidemiology of esophageal cancer]. Turkiye Klinikleri J Surg Med Sci. 2007;3(29):1-4. [Link] 
  15. Yoder LH. Lung cancer epidemiology. Medsurg Nurs. 2006;15(3):171-4; quiz 175. [PubMed] 
  16. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev. 1993;15(2):499-545. [Crossref]  [PubMed] 
  17. Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859-64. [Crossref]  [PubMed] 
  18. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):1397-421. [Crossref]  [PubMed] 
  19. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993;85(22):1819-27. [Crossref]  [PubMed] 
  20. Akazaki K, Stemmerman GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst. 1973;50(5):1137-44. [Crossref]  [PubMed] 
  21. Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer. 1982;29(6):611-6. [Crossref]  [PubMed] 
  22. McMichael AJ, McCall MG, Hartshorne JM, Woodings TL. Patterns of gastro-intestinal cancer in European migrants to Australia: the role of dietary change. Int J Cancer. 1980;25(4):431-7. [Crossref]  [PubMed] 
  23. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst. 1968;40(1):43-68. [PubMed] 
  24. Haenszel W, Kurihara M, Segi M, Lee RK. Stomach cancer among Japanese in Hawaii. J Natl Cancer Inst. 1972;49(4):969-88. [PubMed] 
  25. Lubin JH, Boice JD Jr. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J Natl Cancer Inst. 1997;89(1):49-57. [Crossref]  [PubMed] 
  26. Vecchia C, Bosetti C. Diet and cancer risk in Mediterranean countries. Hungarian Medical Journal. 2007;1(1):13-23. [Crossref] 
  27. La Vecchia C, Bosetti C. Diet and cancer risk in Mediterranean countries: open issues. Public Health Nutr. 2006;9(8A):1077-82. [Crossref]  [PubMed] 
  28. Trichopoulou A, Lagiou P, Kuper H, Trichopoulos D. Cancer and Mediterranean dietary traditions. Cancer Epidemiol Biomarkers Prev. 2000;9(9):869-73. [PubMed] 
  29. Colomer R, Menéndez JA. Mediterranean diet, olive oil and cancer. Clin Transl Oncol. 2006;8(1):15-21. [Crossref]  [PubMed] 
  30. Buiatti E, Palli D, Decarli A, Amadori D, Avellini C, Bianchi S, et al. A case-control study of gastric cancer and diet in Italy. Int J Cancer. 1989;44(4):611-6. [Crossref]  [PubMed] 
  31. Pauwels EK. The protective effect of the Mediterranean diet: focus on cancer and cardiovascular risk. Med Princ Pract. 2011;20(2):103-11. [Crossref]  [PubMed] 
  32. La Vecchia C. Association between Mediterranean dietary patterns and cancer risk. Nutr Rev. 2009;67 Suppl 1:S126-9. [Crossref]  [PubMed] 
  33. Tavani A, La Vecchia C. Fruit and vegetable consumption and cancer risk in a Mediterranean population. Am J Clin Nutr. 1995;61(6 Suppl):1374S-7S. [Crossref]  [PubMed] 
  34. Viuda‐Martos M, Ruiz Navajas Y, Sánchez Zapata E, Fernández‐López J, Pérez‐Álvarez JA. Antioxidant activity of essential oils of five spice plants widely used in a Mediterranean diet. Flavour and Fragrance Journal. 2010;25(1):13-9. [Crossref] 
  35. La Vecchia C. Mediterranean epidemiological evidence on tomatoes and the prevention of digestive-tract cancers. Proceedings of the Society for Experimental Biology and Medicine. 1998;218(2):125-8. [Crossref]  [PubMed] 
  36. Trichopoulou A, Lagiou P. Healthy traditional Mediterranean diet: an expression of culture, history, and lifestyle. Nutr Rev. 1997;55(11 Pt 1):383-9. [Crossref]  [PubMed] 
  37. Franceschi S, Bidoli E, La Vecchia C, Talamini R, D'Avanzo B, Negri E. Tomatoes and risk of digestive-tract cancers. Int J Cancer. 1994;59(2):181-4. [Crossref]  [PubMed] 
  38. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst. 2002;94(5):391-8. [Crossref]  [PubMed] 
  39. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst. 1999;91(4):317-31. [Crossref]  [PubMed] 
  40. Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. J Postgrad Med. 2003;49(3):222-8. [PubMed] 
  41. Sankaranarayanan R, Varghese C, Duffy SW, Padmakumary G, Day NE, Nair MK. A case-control study of diet and lung cancer in Kerala, south India. Int J Cancer. 1994;58(5):644-9. [Crossref]  [PubMed] 
  42. Zain RB. Cultural and dietary risk factors of oral cancer and precancer--a brief overview. Oral Oncol. 2001;37(3):205-10. [Crossref]  [PubMed] 
  43. Phukan RK, Chetia CK, Ali MS, Mahanta J. Role of dietary habits in the development of esophageal cancer in Assam, the north-eastern region of India. Nutr Cancer. 2001;39(2):204-9. [Crossref]  [PubMed] 
  44. Shanmugasundaram KR, Ramanujam S, Shanmugasundaram ER. Amrita Bindu--a salt-spice-herbal health food supplement for the prevention of nitrosamine induced depletion of antioxidants. J Ethnopharmacol. 1994;42(2):83-93. [Crossref]  [PubMed] 
  45. Sengupta A, Ghosh S, Bhattacharjee S, Das S. Indian food ingredients and cancer prevention - an experimental evaluation of anticarcinogenic effects of garlic in rat colon. Asian Pac J Cancer Prev. 2004;5(2):126-32. [PubMed] 
  46. Krishnaswamy K. Traditional Indian spices and their health significance. Asia Pac J Clin Nutr. 2008;17 Suppl 1:265-8. [PubMed] 
  47. Shobana S, Naidu KA. Antioxidant activity of selected Indian spices. Prostaglandins Leukot Essent Fatty Acids. 2000;62(2):107-10. [Crossref]  [PubMed] 
  48. Uma Pradeep K, Geervani P, Eggum BO. Common Indian spices: nutrient composition, consumption and contribution to dietary value. Plant Foods Hum Nutr. 1993;44(2):137-48. [Crossref]  [PubMed] 
  49. Banerjee S, Panda CK, Das S. Clove (Syzygium aromaticum L.), a potential chemopreventive agent for lung cancer. Carcinogenesis. 2006;27(8):1645-54. [Crossref]  [PubMed] 
  50. Prashar A, Locke IC, Evans CS. Cytotoxicity of clove (Syzygium aromaticum) oil and its major components to human skin cells. Cell Prolif. 2006;39(4):241-8. [Crossref]  [PubMed]  [PMC] 
  51. Hussain A, Sasidharan S, Ahmed T, Ahmed M, Sharma C. Clove (Syzygium aromaticum) extract potentiates gemcitabine cytotoxic effect on human cervical cancer cell line. International Journal of Cancer Research. 2009;5(3):95-104. [Crossref] 
  52. Steel FA, Gardiner G. The Complete Indian Housekeeper and Cook. Oxford: Oxford University Press; 2010. [Crossref] 
  53. Yu H, Harris RE, Gao YT, Gao R, Wynder EL. Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol. 1991;20(1):76-81. [Crossref]  [PubMed] 
  54. Li JY. Epidemiology of esophageal cancer in China. Natl Cancer Inst Monogr. 1982;62:113-20. [PubMed] 
  55. Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5 Suppl 1:5-11. [Crossref]  [PubMed] 
  56. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56(1):1-9. [Crossref] 
  57. Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig Dis. 2010;28(4-5):600-3. [Crossref]  [PubMed] 
  58. Kono S, Ikeda M, Tokudome S, Kuratsune M. A case-control study of gastric cancer and diet in northern Kyushu, Japan. Jpn J Cancer Res. 1988;79(10):1067-74. [Crossref]  [PubMed]  [PMC] 
  59. Imai K, Suga K, Nakachi K. Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med. 1997;26(6):769-75. [Crossref]  [PubMed] 
  60. López-Carrillo L, Hernández Avila M, Dubrow R. Chili pepper consumption and gastric cancer in Mexico: a case-control study. Am J Epidemiol. 1994;139(3):263-71. [PubMed] 
  61. López-Carrillo L, López-Cervantes M, Robles-Díaz G, Ramírez-Espitia A, Mohar-Betancourt A, Meneses-García A, et al. Capsaicin consumption, Helicobacter pylori positivity and gastric cancer in Mexico. Int J Cancer. 2003;106(2):277-82. [Crossref]  [PubMed] 
  62. Mori A, Lehmann S, O'Kelly J, Kumagai T, Desmond JC, Pervan M, et al. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res. 2006;66(6):3222-9. [Crossref]  [PubMed] 
  63. Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Vinodhkumar R, Devaki T. Capsaicin modulates pulmonary antioxidant defense system during benzo(a)pyrene-induced lung cancer in Swiss albino mice. Phytother Res. 2008;22(4):529-33. [Crossref]  [PubMed] 
  64. Bley K, Boorman G, Mohammad B, McKenzie D, Babbar S. A comprehensive review of the carcinogenic and anticarcinogenic potential of capsaicin. Toxicol Pathol. 2012;40(6):847-73. [Crossref]  [PubMed] 
  65. López-Carrillo L, López-Cervantes M, Ward MH, Bravo-Alvarado J, Ramírez-Espitia A. Nutrient intake and gastric cancer in Mexico. Int J Cancer. 1999;83(5):601-5. [Crossref]  [PubMed] 
  66. Waterman E, Lockwood B. Active components and clinical applications of olive oil. Altern Med Rev. 2007;12(4):331-42. [PubMed] 
  67. Carluccio MA, Siculella L, Ancora MA, Massaro M, Scoditti E, Storelli C, et al. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol. 2003;23(4):622-9. [Crossref]  [PubMed] 
  68. Omar SH. Oleuropein in olive and its pharmacological effects. Sci Pharm. 2010;78(2):133-54. [Crossref]  [PubMed]  [PMC] 
  69. Bhuvaneswari V, Nagini S. Lycopene: a review of its potential as an anticancer agent. Curr Med Chem Anticancer Agents. 2005;5(6):627-35. [Crossref]  [PubMed] 
  70. Thomson M, Ali M. Garlic [Allium sativum]: a review of its potential use as an anti-cancer agent. Curr Cancer Drug Targets. 2003;3(1):67-81. [Crossref]  [PubMed] 
  71. Dong Y, Lisk D, Block E, Ip C. Characterization of the biological activity of gamma-glutamyl-Se-methylselenocysteine: a novel, naturally occurring anticancer agent from garlic. Cancer Res. 2001;61(7):2923-8. [PubMed] 
  72. Seki T, Hosono T, Hosono-Fukao T, Inada K, Tanaka R, Ogihara J, et al. Anticancer effects of diallyl trisulfide derived from garlic. Asia Pac J Clin Nutr. 2008;17 Suppl 1:249-52. [PubMed] 
  73. Li M, Ciu JR, Ye Y, Min JM, Zhang LH, Wang K, et al. Antitumor activity of Z-ajoene, a natural compound purified from garlic: antimitotic and microtubule-interaction properties. Carcinogenesis. 2002;23(4):573-9. [Crossref]  [PubMed] 
  74. Ariga T, Seki T. Antithrombotic and anticancer effects of garlic-derived sulfur compounds: a review. Biofactors. 2006;26(2):93-103. [Crossref]  [PubMed] 
  75. Milos M, Mastelic J, Jerkovic I. Chemical composition and antioxidant effect of glycosidically bound volatile compounds from oregano (Origanum vulgare L. ssp. hirtum). Food Chemistry. 2000;71(1):79-83. [Crossref] 
  76. Sivropoulou A, Papanikolaou E, Nikolaou C, Kokkini S, Lanaras T, Arsenakis M. Antimicrobial and cytotoxic activities of Origanum essential oils. J Agric Food Chem. 1996;44(5):1202-5. [Crossref] 
  77. Sertel S, Eichhorn T, Plinkert PK, Efferth T. Cytotoxicity of Thymus vulgaris essential oil towards human oral cavity squamous cell carcinoma. Anticancer Res. 2011;31(1):81-7. [PubMed] 
  78. del Ba-o MJ, Lorente J, Castillo J, Benavente-García O, del Río JA, Ortu-o A, et al. Phenolic diterpenes, flavones, and rosmarinic acid distribution during the development of leaves, flowers, stems, and roots of Rosmarinus officinalis. Antioxidant activity. J Agric Food Chem. 2003;51(15):4247-53. [Crossref]  [PubMed] 
  79. Ibá-ez C, Valdés A, García-Ca-as V, Simó C, Celebier M, Rocamora-Reverte L, et al. Global Foodomics strategy to investigate the health benefits of dietary constituents. J Chromatogr A. 2012;1248:139-53. [Crossref]  [PubMed] 
  80. al-Sereiti MR, Abu-Amer KM, Sen P. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials. Indian J Exp Biol. 1999;37(2):124-30. [PubMed] 
  81. Cheung S, Tai J. Anti-proliferative and antioxidant properties of rosemary Rosmarinus officinalis. Oncol Rep. 2007;17(6):1525-31. [Crossref]  [PubMed] 
  82. Lu Y, Yeap Foo L. Antioxidant activities of polyphenols from sage (Salvia officinalis). Food Chemistry. 2001;75(2):197-202. [Crossref] 
  83. Keshavarz M, Bidmeshkipour A, Mostafaie A, Mansouri K, Mohammadi-Motlagh HR. Anti tumor activity of Salvia officinalis is due to its anti-angiogenic, anti-migratory and anti-proliferative effects. J Cell (Yakhteh). 2011;12(4):477-82. [Link] 
  84. Kuttan R, Bhanumathy P, Nirmala K, George MC. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985;29(2):197-202. [Crossref]  [PubMed] 
  85. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006;78(18):2081-7. [Crossref]  [PubMed] 
  86. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23(1A):363-98. [PubMed] 
  87. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 2010;17(3):190-7. [Crossref]  [PubMed] 
  88. Kim JS, Kwon YS, Chun WJ, Kim TY, Sun J, Yu CY, et al. Rhus verniciflua Stokes flavonoid extracts have anti-oxidant, anti-microbial and α-glucosidase inhibitory effect. 2010;120(2):539-43. [Crossref] 
  89. Kim JH, Jung CH, Jang BH, Go HY, Park JH, Choi YK, et al. Selective cytotoxic effects on human cancer cell lines of phenolic-rich ethyl-acetate fraction from Rhus verniciflua Stokes. Am J Chin Med. 2009;37(3):609-20. [Crossref]  [PubMed] 
  90. Mekawey AA, Mokhtar M, Farrag RM. Antitumor and antibacterial activities of [1-(2-ethyl, 6-heptyl) phenol] from Cuminum cyminum seeds. Journal of Applied Sciences Research. 2009;5(11):1881-8. [Link] 
  91. Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 2008;46(2):409-20. [PubMed] 
  92. Sang S, Hong J, Wu H, Liu J, Yang CS, Pan MH, et al. Increased growth inhibitory effects on human cancer cells and anti-inflammatory potency of shogaols from Zingiber officinale relative to gingerols. J Agric Food Chem. 2009;57(22):10645-50. [Crossref]  [PubMed]  [PMC] 
  93. Escribano J, Alonso GL, Coca-Prados M, Fernandez JA. Crocin, safranal and picrocrocin from saffron (Crocus sativus L.) inhibit the growth of human cancer cells in vitro. Cancer Lett. 1996;100(1-2):23-30. [Crossref]  [PubMed] 
  94. Abdullaev FI. Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Biol Med (Maywood). 2002;227(1):20-5. [Crossref]  [PubMed] 
  95. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol. 2004;546:121-65. [Crossref]  [PubMed] 
  96. Popiołkiewicz J, Polkowski K, Skierski JS, Mazurek AP. In vitro toxicity evaluation in the development of new anticancer drugs-genistein glycosides. Cancer Lett. 2005;229(1):67-75. [Crossref]  [PubMed] 
  97. Kerwin SM. Soy saponins and the anticancer effects of soybeans and soy-based foods. Curr Med Chem Anticancer Agents. 2004;4(3):263-72. [Crossref]  [PubMed] 
  98. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. 1999;129(9):1628-35. [Crossref]  [PubMed] 
  99. Chen PN, Chu SC, Chiou HL, Chiang CL, Yang SF, Hsieh YS. Cyanidin 3-glucoside and peonidin 3-glucoside inhibit tumor cell growth and induce apoptosis in vitro and suppress tumor growth in vivo. Nutr Cancer. 2005;53(2):232-43. [Crossref]  [PubMed] 
  100. Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. 2007;55(3):224-36. [Crossref]  [PubMed]  [PMC] 
  101. Ibá-ez C, Simó C, García-Ca-as V, Cifuentes A, Castro-Puyana M. Metabolomics, peptidomics and proteomics applications of capillary electrophoresis-mass spectrometry in Foodomics: a review. Anal Chim Acta. 2013;802:1-13. [Crossref]  [PubMed] 
  102. Capozzi F, Bordoni A. Foodomics: a new comprehensive approach to food and nutrition. Genes Nutr. 2013;8(1):1-4. [Crossref]  [PubMed]  [PMC] 
  103. Valdés A, Simó C, Ibá-ez C, Rocamora-Reverte L, Ferragut JA, García-Ca-as V, et al. Effect of dietary polyphenols on K562 leukemia cells: a Foodomics approach. Electrophoresis. 2012;33(15):2314-27. [Crossref]  [PubMed] 
  104. Ibá-ez C, Valdés A, García-Ca-as V, Simó C, Celebier M, Rocamora-Reverte L, et al. Global Foodomics strategy to investigate the health benefits of dietary constituents. J Chromatogr A. 2012;1248:139-53. [Crossref]  [PubMed] 
  105. García-Ca-as V, Simó C, Herrero M, Ibá-ez E, Cifuentes A. Present and future challenges in food analysis: foodomics. Anal Chem. 2012;84(23):10150-9. [Crossref]  [PubMed] 
  106. Celebier M, Ibá-ez C, Simó C, Cifuentes A. A Foodomics approach: CE-MS for comparative metabolomics of colon cancer cells treated with dietary polyphenols. Methods Mol Biol. 2012;869:185-95. [Crossref]  [PubMed] 
  107. Cifuentes A. Food analysis and foodomics. J Chromatogr A. 2009;1216(43):7109. [Crossref]  [PubMed] 
  108. Bentley DR. The Human Genome Project--an overview. Med Res Rev. 2000;20(3):189-96. [Crossref]  [PubMed] 
  109. Tyers M, Mann M. From genomics to proteomics. Nature. 2003;422(6928):193-7. [Crossref]  [PubMed] 
  110. Mishra NC. Introduction to Proteomics: Principles and Applications. Hoboken, N.J.: John Wiley & Sons; 2010.
  111. Başaran E, Aras S, Cansaran-Duman D. [General outlook and applications of genomics, proteomics and metabolomics]. Türk Hijyen ve Deneysel Biyoloji Dergisi. 2010;67(2):85-96. [Link] 
  112. Denizli A. [Protein analizi]. Tubitak, Bilim ve Teknik Dergisi. 2007;476:66-9. [Link] 
  113. Kurban S, Mehmetoglu İ. [Proteomics]. Yeni Tıp Dergisi. 2010;27:70-5. [Link] 
  114. Türk Eczacılar Birliği Eczacılık Akademisi. Biyokimyada Yeni Uygulamalar: Proteom Analizleri ve Uygulama Alanları Ders Notları. Haziran; 2005.
  115. esmî Gazete (1.12.2000/24247, Tebliğ No: 98/7), Türk Gıda Kodeksi Yemeklik Zeytinyağı ve Yemeklik Prina Yağı Tebliğinde Değişiklik Yapılması Hakkında Tebliğ; 2000. [Link] 
  116. Menendez JA, Lupu R. Mediterranean dietary traditions for the molecular treatment of human cancer: anti-oncogenic actions of the main olive oil's monounsaturated fatty acid oleic acid (18:1n-9). Curr Pharm Biotechnol. 2006;7(6):495-502. [Crossref]  [PubMed] 
  117. Menendez JA, Vellon L, Colomer R, Lupu R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Ann Oncol. 2005;16(3):359-71. [Crossref]  [PubMed] 
  118. Eliyatkın N, Zengel B, Aktaş S. [Importance of HER2/NEU (C-ERB-B2) status in breast cancer: which method is more effective to evaluate of HER-2 status?]. J Breast Health. 2013;9:175-81. [Crossref] 
  119. la Vecchia C, Negri E, Franceschi S, Decarli A, Giacosa A, Lipworth L. Olive oil, other dietary fats, and the risk of breast cancer (Italy). Cancer Causes Control. 1995;6(6):545-50. [Crossref]  [PubMed] 
  120. Trichopoulou A, Katsouyanni K, Stuver S, Tzala L, Gnardellis C, Rimm E, et al. Consumption of olive oil and specific food groups in relation to breast cancer risk in Greece. J Natl Cancer Inst. 1995;87(2):110-6. [Crossref]  [PubMed] 
  121. Kim GY, Kim JH, Ahn SC, Lee HJ, Moon DO, Lee CM, et al. Lycopene suppresses the lipopolysaccharide-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB. Immunology. 2004;113(2):203-11. [Crossref]  [PubMed]  [PMC] 
  122. Sharoni Y, Danilenko M, Levy J. Molecular mechanisms for the anticancer activity of the carotenoid lycopene. Drug Development Research. 2000;50(3-4):448-56. [Link] 
  123. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279(5350):563-6. [Crossref]  [PubMed] 
  124. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351(9113):1393-6. [Crossref]  [PubMed] 
  125. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev. 1999;4(5):304-29. [PubMed] 
  126. Ahmad N, Katiyar SK, Mukhtar H. Antioxidants in chemoprevention of skin cancer. Curr Probl Dermatol. 2001;29:128-39. [Crossref]  [PubMed] 
  127. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM. Antioxidants and cancer therapy: a systematic review. J Clin Oncol. 2004;22(3):517-28. [Crossref]  [PubMed] 
  128. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1-40. [Crossref]  [PubMed] 
  129. Chung LY. The antioxidant properties of garlic compounds: allyl cysteine, alliin, allicin, and allyl disulfide. J Med Food. 2006;9(2):205-13. [Crossref]  [PubMed] 
  130. Tsubura A, Lai YC, Kuwata M, Uehara N, Yoshizawa K. Anticancer effects of garlic and garlic-derived compounds for breast cancer control. Anticancer Agents Med Chem. 2011;11(3):249-53. [Crossref]  [PubMed] 
  131. Nakatani N. Phenolic antioxidants from herbs and spices. Biofactors. 2000;13(1-4):141-6. [Crossref]  [PubMed] 
  132. akatani N. Antioxidants from spices and herbs. In: Shahidi F, ed. Natural Antioxidants: Chemistry, Health Effects, and Applications. Champaign, Illinois: The American Oil Chemists Society; 1997. p.64-75.
  133. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr. 2005;81(1 Suppl):317S-25S. [Crossref]  [PubMed] 
  134. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. Am J Clin Nutr. 2005;81(1 Suppl):215S-7S. [Crossref]  [PubMed] 
  135. Scalbert A, Manach C, Morand C, Rémésy C, Jiménez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr. 2005;45(4):287-306. [Crossref]  [PubMed] 
  136. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007;12(3):271-80. [Crossref]  [PubMed] 
  137. Pasquier E, Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life. 2008;60(3):165-70. [Crossref]  [PubMed] 
  138. Petersen M, Simmonds MS. Rosmarinic acid. Phytochemistry. 2003;62(2):121-5. [Crossref]  [PubMed] 
  139. Huang SS, Zheng RL. Rosmarinic acid inhibits angiogenesis and its mechanism of action in vitro. Cancer Lett. 2006;239(2):271-80. [Crossref]  [PubMed] 
  140. Turgut B, Güler M, Demir T, Türkçüoğlu P, Çeliker Ü. [The role of vascular endothelial growth factor in ocular angiogenesis]. Turkiye Klinikleri J Ophthalmol. 2007;16(1):38-46. [Link] 
  141. Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res. 2008;52(5):507-26. [Crossref]  [PubMed] 
  142. Lu Y, Foo LY. Flavonoid and phenolic glycosides from Salvia officinalis. Phytochemistry. 2000;55(3):263-7. [Crossref]  [PubMed] 
  143. Çimen MBY. [Flavonoids and their antioxidant properties]. Turkiye Klinikleri J Med Sci. 1999;19(5):296-304. [Link] 
  144. Kahraman A, Serteser M, Köken T. [Flavonoids]. The Medical Journal of Kocatepe. 2002;3(1):1-8. [Link] 
  145. Ren W, Qiao Z, Wang H, Zhu L, Zhang L. Flavonoids: promising anticancer agents. Med Res Rev. 2003;23(4):519-34. [Crossref]  [PubMed] 
  146. Galati G, O'Brien PJ. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med. 2004;37(3):287-303. [Crossref]  [PubMed] 
  147. Jang HS, Kook SH, Son YO, Kim JG, Jeon YM, Jang YS, et al. Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochim Biophys Acta. 2005;1726(3):309-16. [Crossref]  [PubMed] 
  148. Zhang JH, Zhang Y, Herman B. Caspases, apoptosis and aging. Ageing Res Rev. 2003;2(4):357-66. [Crossref]  [PubMed] 
  149. Gupta S, Knowlton AA. HSP60, Bax, apoptosis and the heart. J Cell Mol Med. 2005;9(1):51-8. 15784164; PMCID: PMC6741334 [Crossref]  [PubMed]  [PMC] 
  150. eed JC. Balancing cell life and death: bax, apoptosis, and breast cancer. J Clin Invest. 1996;97(11):2403-4. ; PMCID: [Crossref]  [PubMed]  [PMC] 
  151. Jung NC, Na CS, Na ES. Process for the preparation of Rhus verniciflua extract and anti-cancer composition containing same. Google Patents; 2000.
  152. Choi WC, Kwon SP, Park SJ. Process for preparation of Rhus verniciflua extracts having excellent anti-cancer activity and anti-cancer pharmaceutical composition containing the same. Google Patents; 2009.
  153. Mekawey AA, Mokhtar M, Farrag RM. Antitumor and antibacterial activities of [1-(2-ethyl, 6-heptyl) phenol] from Cuminum cyminum seeds. Journal of Applied Sciences Research. 2009;5(11):1881-8. [Link] 
  154. Mnif S, Aifa S. Cumin (Cuminum cyminum L.) from traditional uses to potential biomedical applications. Chem Biodivers. 2015;12(5):733-42. [Crossref]  [PubMed] 
  155. Ströfer M, Jelkmann W, Depping R. Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF. Strahlenther Onkol. 2011;187(7):393-400. [Crossref]  [PubMed] 
  156. Mahady GB, Pendland SL, Yun GS, Lu ZZ, Stoia A. Ginger (Zingiber officinale Roscoe) and the gingerols inhibit the growth of Cag A+ strains of Helicobacter pylori. Anticancer Res. 2003;23(5A):3699-702. [PubMed]  [PMC] 
  157. Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci A, Ploegh HL. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci U S A. 2011;108(22):9238-43. [Crossref]  [PubMed]  [PMC] 
  158. Park YJ, Wen J, Bang S, Park SW, Song SY. [6]-Gingerol induces cell cycle arrest and cell death of mutant p53-expressing pancreatic cancer cells. Yonsei Med J. 2006;47(5):688-97. [Crossref]  [PubMed]  [PMC] 
  159. Lee SH, Cekanova M, Baek SJ. Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. Mol Carcinog. 2008;47(3):197-208. [Crossref]  [PubMed]  [PMC] 
  160. Hong ZF, Zhao WX, Yin ZY, Xie CR, Xu YP, Chi XQ, et al. Capsaicin enhances the drug sensitivity of cholangiocarcinoma through the inhibition of chemotherapeutic-induced autophagy. PLoS One. 2015;10(5):e0121538. [Crossref]  [PubMed]  [PMC] 
  161. Díaz-Laviada I, Rodríguez-Henche N. The potential antitumor effects of capsaicin. Prog Drug Res. 2014;68:181-208. [Crossref]  [PubMed] 
  162. Srinivasan K. Biological activities of red pepper (Capsicum annuum) and its pungent principle capsaicin: a review. Crit Rev Food Sci Nutr. 2016;56(9):1488-500. [Crossref]  [PubMed] 
  163. Lewinska A, Jarosz P, Czech J, Rzeszutek I, Bielak-Zmijewska A, Grabowska W, et al. Capsaicin-induced genotoxic stress does not promote apoptosis in A549 human lung and DU145 prostate cancer cells. Mutat Res Genet Toxicol Environ Mutagen. 2015;779:23-34. [Crossref]  [PubMed] 
  164. Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J. Soy and breast cancer: focus on angiogenesis. Int J Mol Sci. 2015;16(5):11728-49. [Crossref]  [PubMed]  [PMC] 
  165. Adjakly M, Bosviel R, Rabiau N, Boiteux JP, Bignon YJ, Guy L, et al. DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics. 2011;3(6):795-803. [PubMed] 
  166. Takagi A, Kano M, Kaga C. Possibility of breast cancer prevention: use of soy isoflavones and fermented soy beverage produced using probiotics. Int J Mol Sci. 2015;16(5):10907-20. [Crossref]  [PubMed]  [PMC] 
  167. Panda PK, Mukhopadhyay S, Behera B, Bhol CS, Dey S, Das DN, et al. Antitumor effect of soybean lectin mediated through reactive oxygen species-dependent pathway. Life Sci. 2014;111(1-2):27-35. Erratum in: Life Sci. 2019;231:116552. [Crossref]  [PubMed] 
  168. Cojocneanu Petric R, Braicu C, Raduly L, Zanoaga O, Dragos N, Monroig P, et al. Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers. Onco Targets Ther. 2015;8:2053-66. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com